Glufosfamide

Summary

Glufosfamide (CHEMBL2107143) is a phase-3 clinical-stage small molecule; indicated across 7 conditions including exocrine pancreatic carcinoma and pancreatic neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 7 conditions
• Clinical trials: 9
• Chemistry: 383.16 Da · C10H21Cl2N2O7P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107143
Name	Glufosfamide
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	123628
Molecular formula	C10H21Cl2N2O7P
Molecular weight	383.16
InChIKey	PSVUJBVBCOISSP-SPFKKGSWSA-N

SMILES: C(CCl)NP(=O)(NCCCl)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O

IUPAC name: (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol

Also known as: D 19575, D-19575, D19575, Glucosylifosfamide mustard, Glufosfamida, Glufosfamide, GLUFOSFAMIDE

Patent coverage: 1,720 distinct patent families (7,524 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
exocrine pancreatic carcinoma	3	MONDO:0005192	EFO:0002618
pancreatic neoplasm	3	MONDO:0021040	EFO:0003860
small cell lung carcinoma	2	MONDO:0008433	EFO:0000702
soft tissue sarcoma	2	MONDO:0018078	EFO:1001968
central nervous system neoplasm	2	MONDO:0006130	EFO:1000158
ovarian cancer	2	MONDO:0008170	MONDO:0008170
lung neoplasm	2	MONDO:0021117	MONDO:0008903

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE2	6
PHASE3	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01954992	PHASE3	RECRUITING	Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
NCT00099294	PHASE3	COMPLETED	Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer
NCT00005053	PHASE2	COMPLETED	Glufosfamide With or Without Hydration in Treating Patients With Advanced Pancreatic Cancer
NCT00005055	PHASE2	COMPLETED	Glufosfamide With of Without Hydration in Treating Patients With Advanced Non-small Cell Lung Cancer
NCT00014300	PHASE2	COMPLETED	Glufosfamide in Treating Patients With Recurrent Glioblastoma Multiforme
NCT00102752	PHASE1/PHASE2	COMPLETED	Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer
NCT00435578	PHASE2	TERMINATED	Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma
NCT00441467	PHASE2	COMPLETED	Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma
NCT00442598	PHASE2	TERMINATED	Safety and Efficacy Study of Glufosfamide in Ovarian Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).